RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 Study with RHB-204 for NTM Infections
July 31, 2020 07:00 ET
|
RedHill Biopharma Ltd.
RHB-204 is a potential first-line oral treatment for pulmonary nontuberculous mycobacteria (NTM) infections, a rare disease with no FDA-approved first-line therapy --The pivotal Phase 3 study aims to...
RedHill Biopharma Initiates Global Phase 2/3 Study for COVID-19
July 30, 2020 07:00 ET
|
RedHill Biopharma Ltd.
The global Phase 2/3 study will enroll up to 270 patients with severe COVID-19 across 40 clinical sites; The study has been approved in the UK and Russia and is under review in Italy, Brazil and...
RedHill Biopharma Publishes Positive IBS-D Phase 2 Study Data in The American Journal of Gastroenterology
July 28, 2020 09:35 ET
|
RedHill Biopharma Ltd.
Publication of the Phase 2 U.S. study data show that RHB-102 (Bekinda®) 12mg delivers a clinically meaningful improvement in overall stool consistency response versus placebo in patients with...
RedHill Biopharma Increases Patient Access to Talicia® with EnvisionRx Formularies
July 27, 2020 07:00 ET
|
RedHill Biopharma Ltd.
Talicia® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection designed as a first-line option to address the high and growing resistance of H. pylori to...
RedHill Biopharma acelera el Programa COVID-19 fase 2/3 con la adición de Brasil y México
July 24, 2020 08:00 ET
|
RedHill Biopharma Ltd.
Proceso de estudio de fase 2/3 iniciado en Brasil y México El estudio global de fase 2/3 con administración de opaganib en pacientes con COVID-19 grave ya fue aprobado en el Reino Unido y Rusia Se...
RedHill Biopharma beschleunigt mit der Ausweitung auf Brasilien und Mexiko COVID-19-Programm der Phase II/III
July 24, 2020 01:00 ET
|
RedHill Biopharma Ltd.
Verfahren für Studie der Phase II/III in Brasilien und Mexiko eingeleitet Die globale Studie der Phase II/III mit Opaganib für die Behandlung von schwer erkrankten COVID-19-Patienten wurde im...
RedHill Biopharma加速针对新冠肺炎的2/3期研究计划并将范围扩展到巴西和墨西哥
July 23, 2020 19:00 ET
|
RedHill Biopharma Ltd.
2/3期研究在巴西和墨西哥启动 使用opaganib治疗新冠肺炎重症患者的全球2/3期研究已在英国和俄罗斯获得批准 患者招募计划注册计划在本月启动——在最多40处临床地点招募270名受试者 计划于2020年第4季度提交紧急使用授权申请 在美国同时进行的针对重症新冠肺炎的2期研究预计预计将于8月完成 以色列特拉维夫和北卡罗来纳州罗利, July 24, 2020 (GLOBE...
RedHill Biopharma 加入巴西和墨西哥，現正加速第 2/3 期 COVID-19 計劃
July 23, 2020 19:00 ET
|
RedHill Biopharma Ltd.
第 2/3 期研究過程已在巴西和墨西哥啟動 全球第 2/3 期 opaganib 用於嚴重 COVID-19 患者的研究已獲批准在英國及俄羅斯展開 將於本月開始在多達 40 個臨床中心為計劃納入 270 名受試者 預計於 2020 年第 4 季可能提交緊急用途申請 預計將於 8 月完成嚴重 COVID-19 美國第 2 階段平行研究的納入工作 以色列特拉維夫和北卡羅萊納州拉里格, July...
RedHill Biopharma accélère la phase 2/3 du programme sur la maladie COVID-19 avec l'ajout du Brésil et du Mexique
July 23, 2020 09:36 ET
|
RedHill Biopharma Ltd.
La phase 2/3 du processus d'étude a été initiée au Brésil et au Mexique L'étude mondiale de phase 2/3 sur l'opaganib chez des patients atteints d'une infection grave à la maladie COVID-19 a déjà été...
RedHill Biopharma Acelera o Programa COVID-19 Fase 2/3 com a Inclusão do Brasil e México
July 23, 2020 06:00 ET
|
RedHill Biopharma Ltd.
Processo da fase 2/3 do estudo iniciado no Brasil e no México O estudo global de Fase 2/3 com a administração do opaganib em pacientes com COVID-19 grave já foi aprovado no Reino Unido e na Rússia...